MGMT and PTEN as potential prognostic markers in breast cancer
- 29 February 2012
- journal article
- Published by Elsevier BV in Experimental and Molecular Pathology
- Vol. 92 (1), 20-26
- https://doi.org/10.1016/j.yexmp.2011.09.019
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- DNA repair pathways as targets for cancer therapyNature Reviews Cancer, 2008
- MGMT hypermethylation: A prognostic foe, a predictive friendDNA Repair, 2007
- MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agentsDNA Repair, 2007
- Epidemiology of basal-like breast cancerBreast Cancer Research and Treatment, 2007
- Targeted Modulation of MGMT: Clinical ImplicationsClinical Cancer Research, 2006
- MGMT: its role in cancer aetiology and cancer therapeuticsNature Reviews Cancer, 2004
- Expression and Prognostic Significance ofO 6-Methylguanine-DNA Methyltransferase in Hepatocellular, Gastric, and Breast CancersAnnals of Surgical Oncology, 2001
- Loss of Expression of the PTEN Gene Protein Product Is Associated with Poor Outcome in Breast CancerLaboratory Investigation, 2001
- Methylation of selected CpGs in the humanO6-methylguanine-DNA methyltransferase promoter region as a marker of gene silencingMolecular Carcinogenesis, 1999
- Lack of the DNA repair protein O6-methylguanine-DNA methyltransferase in histologically normal brain adjacent to primary human brain tumors.Proceedings of the National Academy of Sciences of the United States of America, 1996